Schumm-Draeger 2015

NCT01217892

1 Treatments

Studied treatment  Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD

Control treatment  placebo

Concomittant treatments  -

2 Patients

Patients  Patients With Type 2 Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy

Inclusion criteria  -

Exclusion criteria  -

3 Methods

Blinding  -

Design  -

Centers  -

Geographical area  -

Sizes  -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>MI</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause deaths</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV deaths</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>stroke</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References